This move is archived. Current quotes and coverage live on the stock page.
Follow HLS
HLS Therapeutics Inc experienced a notable decline in stock value, raising concerns among investors.
HLS Therapeutics Inc's stock fell by 4.95% yesterday, closing at CA$3.65. This drop follows a series of mixed financial results that may have contributed to investor uncertainty.
Investor takeaway: Investors should closely monitor HLS Therapeutics' financial performance and market conditions, as recent results indicate volatility and potential challenges ahead.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$129.93M
52W high
$5.64
52W low
$3.56
1W change
+7.97%
Beta
0.76
Analyst Price Targets
Based on analyst covering HLS · as of Oct 9, 2026
Wall Street analysts forecast HLS stock price to rise 78.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.49
+78.3% Upside
Previously C$7.52 on Oct 8, 2026
Current Price
C$4.20
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
47.9%
Annualized
90-Day Vol
38.4%
Annualized
Trend (90d)
+6.0%
Annualized drift
90d Mean
C$4.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.23 | C$3.59 – C$4.99 |
| 60 trading days | C$4.26 | C$3.37 – C$5.38 |
| 90 trading days | C$4.29 | C$3.22 – C$5.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Despite the recent decline, HLS Therapeutics has shown growth in revenue and cash flow in previous quarters. This suggests that there’s potential for recovery if the company can keep up its positive momentum.
Bear case
The recent 4.95% drop highlights ongoing concerns about profitability. The company has reported negative profit margins and fluctuating sales figures, which could make investors hesitant.
Recent Performance Overview
HLS Therapeutics Inc's stock fell by 4.95% yesterday, marking a significant decline in investor confidence. The market cap now stands at approximately CA$118.79 million, reflecting the challenges the company faces in achieving profitability.
Advertisement
Financial Results and Market Sentiment
The company's recent financial results have been mixed. While there was revenue growth reported in previous quarters, persistent negative profit margins remain a concern. Investors may view this decline as a signal to reassess their positions, especially given the company's fluctuating sales performance.
Looking Ahead
As HLS Therapeutics navigates its financial landscape, investors should keep a close eye on upcoming earnings reports and market trends. There is potential for recovery, but it depends on the company's ability to stabilize its operations and improve profitability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
